A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

Ebola transmission has been ongoing in the Democratic Republic of Congo since August 2018. In this trial of MAb114, REGN-EB3, remdesivir, and ZMapp (as the control), mortality from Ebola virus disease was lower in the MAb114 and REGN-EB3 groups than in the other groups.

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 381; no. 24; pp. 2293 - 2303
Main Authors:	Mulangu, Sabue, Dodd, Lori E, Davey, Richard T, Tshiani Mbaya, Olivier, Proschan, Michael, Mukadi, Daniel, Lusakibanza Manzo, Mariano, Nzolo, Didier, Tshomba Oloma, Antoine, Ibanda, Augustin, Ali, Rosine, Coulibaly, Sinaré, Levine, Adam C, Grais, Rebecca, Diaz, Janet, Lane, H. Clifford, Muyembe-Tamfum, Jean-Jacques, the PALM Writing Group
Format:	Journal Article
Language:	English
Published:	United States Massachusetts Medical Society 12-12-2019
Subjects:	Adenosine Monophosphate - analogs & derivatives Adolescent Adult Alanine - adverse effects Alanine - analogs & derivatives Alanine - therapeutic use Allergies Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antiviral agents Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Antiviral drugs Child Child, Preschool Consortia Creatinine Democratic Republic of the Congo - epidemiology Disease Outbreaks DNA-directed RNA polymerase Drug dosages Ebola virus Ebolavirus Ebolavirus - genetics Epidemics Female Hemorrhagic Fever, Ebola - drug therapy Hemorrhagic Fever, Ebola - mortality Humans Infant Infant, Newborn Infectious diseases Infusions, Intravenous Intravenous administration Male Monoclonal antibodies Mortality Outbreaks R&D Research & development Ribonucleic acid Ribonucleotides - adverse effects Ribonucleotides - therapeutic use RNA RNA polymerase RNA viruses RNA, Viral - blood Single-Blind Method Young Adult Democratic Republic of the Congo Congo-Democratic Republic of Congo United States > US West Africa
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Ebola transmission has been ongoing in the Democratic Republic of Congo since August 2018. In this trial of MAb114, REGN-EB3, remdesivir, and ZMapp (as the control), mortality from Ebola virus disease was lower in the MAb114 and REGN-EB3 groups than in the other groups.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 Drs. Mulangu, Dodd, and Davey and Drs. Lane and Muyembe-Tamfum contributed equally to this article.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa1910993